Literature DB >> 16140932

Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation.

Tsutomu Kanehira1, Tatsuo Tani, Tetsuo Takagi, Yuichirou Nakano, Eric F Howard, Masaaki Tamura.   

Abstract

To clarify an involvement of angiotensin II signaling in lung neoplasia, we have examined the effect of angiotensin II receptor deficiency on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis. Male angiotensin II type 2 receptor (AT2)-null mice with an SWR/J genetic background and control wild-type mice were treated with NNK (100 mg/kg, i.p.) or saline vehicle. NNK treatment caused the development of lung tumors in all wild-type control mice (100 % tumor prevalence), but only 85% of AT2-null mice developed tumors. The tumor multiplicity in AT2-null mice (1.9 +/- 0.3) was significantly smaller than that in wild-type mice (4.1 +/- 0.9). Primary cultured lung fibroblasts prepared from both AT2-null and wild-type mice markedly increased the colony counts of A549 lung cancer cells in soft agar, but a consistently higher colony count was observed with the wild-type fibroblasts (fold increase in colony number, 5.6 +/- 0.5) than with the AT2-null fibroblasts (3.5 +/- 0.8). The underlying mechanism by which angiotensin II regulates cancer cell growth is due to the regulation of active transforming growth factor-beta (TGF-beta) production. Although the total level of TGF-beta was significantly stimulated when A549 cells were cocultured with either type of fibroblasts, the level of active TGF-beta in the conditioned medium was consistently higher with AT2-null fibroblasts than with wild-type fibroblasts. These results imply that the AT2 receptor negatively regulates the level of active TGF-beta and thus increases NNK-induced lung tumorigenesis. The AT2 receptor function in lung stromal fibroblasts may be a potential modulator of tumor susceptibility in chemical carcinogen-induced lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140932     DOI: 10.1158/0008-5472.CAN-05-0275

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells.

Authors:  Lara Pickel; Takaya Matsuzuka; Chiyo Doi; Rie Ayuzawa; Dharmendra Kumar Maurya; Sheng-Xue Xie; Cory Berkland; Masaaki Tamura
Journal:  Cancer Biol Ther       Date:  2009-12-22       Impact factor: 4.742

2.  Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice.

Authors:  Chiyo Doi; Noboru Egashira; Atsushi Kawabata; Dharmendra Kumar Maurya; Naomi Ohta; Deepthi Uppalapati; Rie Ayuzawa; Lara Pickel; Yuka Isayama; Deryl Troyer; Susumu Takekoshi; Masaaki Tamura
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

3.  Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth.

Authors:  Atsushi Kawabata; Abdulgader Baoum; Naomi Ohta; Stephanie Jacquez; Gwi-Moon Seo; Cory Berkland; Masaaki Tamura
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

Review 4.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

5.  Angiotensin II bi-directionally regulates cyclooxygenase-2 expression in intestinal epithelial cells.

Authors:  Tatsuo Tani; Rie Ayuzawa; Tetsuo Takagi; Tsutomu Kanehira; Dharmendra Kumar Maurya; Masaaki Tamura
Journal:  Mol Cell Biochem       Date:  2008-06-10       Impact factor: 3.396

6.  Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT(2) receptor: evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung.

Authors:  Masaaki Tamura; Heping Yan; Ofelia Zegarra-Moro; Jennifer Edl; Stephanie Oursler; Cindy Chard-Bergstrom; Gordon Andrews; Tsutomu Kanehira; Susumu Takekoshi; Ray Mernaugh
Journal:  J Mol Histol       Date:  2008-04-28       Impact factor: 2.611

7.  NNK-Induced Lung Tumors: A Review of Animal Model.

Authors:  Hua-Chuan Zheng; Yasuo Takano
Journal:  J Oncol       Date:  2011-04-27       Impact factor: 4.375

Review 8.  A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

Authors:  Helmy M Siragy
Journal:  Vasc Health Risk Manag       Date:  2011-05-19

9.  Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.

Authors:  Yi-Ying Chiang; Kuen-Bao Chen; Tung-Han Tsai; Wen-Chen Tsai
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-11-08       Impact factor: 3.738

Review 10.  Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Authors:  Paul Zarogouldis; Nikos K Karamanos; Konstantinos Porpodis; Kalliopi Domvri; Haidong Huang; Wolfgang Hohenforst-Schimdt; Eugene P Goldberg; Konstantinos Zarogoulidis
Journal:  Int J Mol Sci       Date:  2012-08-29       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.